首页> 外文期刊>Pharmaceutical Nanotechnology >Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
【24h】

Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases

机译:抗原特异性免疫耐受治疗自身免疫性疾病的微观和纳米策略。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

An improper immune response towards a self-antigen can result in an autoimmune disease. Commonly these diseases are treated with therapies that suppress overall immune responses, which can lead to increased risk of infection and cancer. A more specific method would be to induce immune tolerance in an antigen specific manner. This is much like traditional vaccines that have antigen specificity towards the pathogen they are forming protection. This antigen specific protection is called immune tolerance and has been accomplished by introducing soluble antigen to mucosal routes (e.g. oral, nasal or sublingual). Unfortunately, this approach has shown limited success clinically. Nano and microparticles (MPs) have recently been applied as delivery vehicles to help improve efficacy in immune tolerance. MPs can increase the solubility and circulation of cargo and passively target macrophages and dendritic cells. Fabrication of MPs with disease-associated antigens has limited disease progression in animal models of Multiple Sclerosis, Type 1 Diabetes, and Rheumatoid Arthritis, which has corresponded to an antigen specific decrease in inflammatory responses. The use of MPs to induce antigen specific tolerance can limit the current therapeutic shortfalls such as adverse drug side effects and blanket suppression of the immune system, which can lead to an overall significant increase in patient quality of life.
机译:对自身抗原的免疫反应不当会导致自身免疫性疾病。通常,这些疾病可以通过抑制整体免疫反应的疗法来治疗,这可能导致感染和癌症的风险增加。更具体的方法是以抗原特异性方式诱导免疫耐受。这很像传统疫苗,它们对正在形成保护作用的病原体具有抗原特异性。这种抗原特异性保护被称为免疫耐受,并且已经通过将可溶性抗原引入粘膜途径(例如口服,鼻内或舌下)来实现。不幸的是,这种方法在临床上显示出有限的成功。纳米和微粒(MPs)最近已被用作递送载体,以帮助提高免疫耐受的功效。 MP可以增加货物的溶解度和循环,并被动地靶向巨噬细胞和树突状细胞。具有疾病相关抗原的MP的制造在多发性硬化症,1型糖尿病和类风湿关节炎的动物模型中限制了疾病的进展,这与炎症反应中抗原的特异性减少相对应。 MP诱导抗原特异性耐受的使用可以限制当前的治疗不足,例如药物副作用和免疫系统的全面抑制,这可能导致患者生活质量的总体显着提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号